SCHEMBL9635580

SCHEMBL9635580

CC(=O)Oc1ccc([N+](=O)[O-])c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.51
CYP3A4 P08684 1/20 0.50
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
NPC1 O15118 2/20 0.46
TLR9 Q9NR96 2/20 0.46
MAPT P10636 4/20 0.44
POLB P06746 2/20 0.44
MAOB P27338 1/20 0.43
PKM P14618 1/20 0.43
ABCC3 O15438 1/20 0.43
ABCC4 O15439 1/20 0.43
NR1I2 O75469 1/20 0.43
ABCB11 O95342 1/20 0.43
TTR P02766 1/20 0.43
NR3C1 P04150 1/20 0.43
PGR P06401 1/20 0.43
HTR1A P08908 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
RARB P10826 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377595 0.87 MAPK1 (0.51) GPR35CYP3A4KMT2AMEN1NPC1
SCHEMBL823830 0.86 ALDH1A1 (0.50) CYP3A4KMT2AMEN1NPC1TLR9
SCHEMBL1429398 0.83 TSHR (0.54) KMT2AMEN1NPC1TLR9MAPT
SCHEMBL16295396 0.83 KDM4E (0.54) CYP3A4KMT2AMEN1NPC1TLR9
SCHEMBL20476360 0.83 GPR35 (0.47) GPR35CYP3A4KMT2ANPC1MAPT
SCHEMBL9368502 0.82 MAPT (0.60) CYP3A4KMT2AMEN1NPC1TLR9
SCHEMBL1857266 0.82 MAPK1 (0.51) CYP3A4KMT2AMEN1NPC1TLR9
SCHEMBL27357985 0.82 ATM (0.51) CYP3A4KMT2AMEN1NPC1TLR9
SCHEMBL1852678 0.81 GPR35 (0.56) GPR35CYP3A4KMT2ANPC1MAPT
SCHEMBL11341366 0.81 NPC1 (0.47) CYP3A4KMT2AMEN1NPC1TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0296221-B1 PROCESS FOR PREPARING 4,6-DINITRORESORCINOL THE DOW CHEMICAL COMPANY (US) 1992-05-13 EP claimed
EP-0296221-A4 PROCESS FOR PREPARING 4,6-DINITRORESORCINOL. STANFORD RES INST INT (US) 1989-04-24 EP claimed
EP-0296221-A1 PROCESS FOR PREPARING 4,6-DINITRORESORCINOL. STANFORD RES INST INT (US) 1988-12-28 EP claimed
WO-1988005038-A1 PROCESS FOR PREPARING 4,6-DINITRORESORCINOL SRI INTERNATIONAL (US) 1988-07-14 WO claimed
US-4745232-A NITRATION, PRECIPITATION SRI INTERNATIONAL (US) 1988-05-17 US claimed
US-10123978-B2 Patch for treating dermatophytosis MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-11-13 US disclosed
EP-2881114-B1 ANTI-TRICHOPHYTIC ADHESIVE PATCH MEIJI SEIKA PHARMA CO LTD (JP) 2018-09-05 EP disclosed
US-20180200199-A1 PATCH FOR TREATING DERMATOPHYTOSIS MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-07-19 US disclosed
US-9549988-B2 Pharmaceutical compounds targeted by MIF affinity-tethered moieties RJS Biologics (US) 2017-01-24 US disclosed
EP-2669274-B1 TOPICAL ANTIFUNGAL AGENT MEIJI SEIKA PHARMA CO LTD (JP) 2015-11-18 EP disclosed
CN-103339112-B Topical antifungal agents MEIJI SEIKA PHARMA CO.,LTD. (JP) 2015-08-12 CN disclosed
US-20150209301-A1 PATCH FOR ANTI-DERMATOPHYTOSIS NICHIBAN COMPANY LIMITED (JP) 2015-07-30 US disclosed
CN-1699363-A Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2005-11-23 CN disclosed
CN-1483024-A Vla-4 inhibitors ��һ��������ҩ��ʽ���� 2004-03-17 CN disclosed
CN-1350534-A Substituted bicyclic heteroaryl compounds as integrin antagonists AVENTIS PHARMA LTD (GB) 2002-05-22 CN disclosed
EP-0296221-B1 PROCESS FOR PREPARING 4,6-DINITRORESORCINOL THE DOW CHEMICAL COMPANY (US) 1992-05-13 EP disclosed
EP-0296221-A4 PROCESS FOR PREPARING 4,6-DINITRORESORCINOL. STANFORD RES INST INT (US) 1989-04-24 EP disclosed
EP-0296221-A1 PROCESS FOR PREPARING 4,6-DINITRORESORCINOL. STANFORD RES INST INT (US) 1988-12-28 EP disclosed
WO-1988005038-A1 PROCESS FOR PREPARING 4,6-DINITRORESORCINOL SRI INTERNATIONAL (US) 1988-07-14 WO disclosed
US-4745232-A NITRATION, PRECIPITATION SRI INTERNATIONAL (US) 1988-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180200199-A1 PATCH FOR TREATING DERMATOPHYTOSIS DPM1, KRT18, LCP1 GPR35 3028/4885CYP3A4 4647/4885KMT2A 183/4885
US-10123978-B2 Patch for treating dermatophytosis DPM1, KRT18, LCP1 GPR35 3028/4885CYP3A4 4647/4885KMT2A 183/4885
US-20150209301-A1 PATCH FOR ANTI-DERMATOPHYTOSIS CUTA, NACA, POLR1C GPR35 2468/4885CYP3A4 4282/4885KMT2A 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.